FibroBiologics' Preclinical Trial Of Degenerative Joints Demonstrates Chondrocyte Spheroids Repairs Cartilage
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic
FibroBiologics tested a new way to fix damaged cartilage in joints using special cell spheres, and early results in the lab look promising. When a company shows its science is working, it's worth watching to see if it moves forward to human testing and eventually helps patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.